Treated in only 3 VISITS!   214.379.2700
  • Imaging Test May Offer Way to Detect Prostate Cancer Early

    Routine early screening for prostate cancer has been largely credited with a sharp decline in the number of deaths attributed to this disease each year. In fact, while an estimated 180,000 American men are diagnosed annually, only about 26,000 die from the disease. A relatively recent development in prostate cancer screening, however, has given rise to fears that these...

  • Genetic, Molecular Testing Shows Promise in Prostate Cancer

    While a replacement for the prostate-specific antigen test for early screening of prostate cancer has not yet been identified, prognostic tests currently available and those under development offer hope for more targeted treatments when the disease is diagnosed. Clinicians say molecular and gene tests can offer insights that better guide the treatment decision-making process. Molecular assays are already making headway...

  • Sexual Activity May Cause PSA Fluctuations After Cancer Treatment

    Men who are treated for prostate cancer using curative radiation therapy techniques, such as brachytherapy, may get a surprise they’re not expecting during routine follow-up prostate-specific antigen tests. A bounce in the numbers that occurs in some cases is no major cause for alarm though, researchers say. This up-and-down fluctuation in numbers is believed to be caused by nothing...

  • Prostate Cancer Metastasis Site Impacts Survival

    Getting a diagnosis of metastatic prostate cancer can be devastating. The news, however, isn’t always as bad as it might seem. Researchers are finding that the metastasis location can greatly impact survival rates in prostate cancer. To gain a better understanding of how metastasis site impacts prognosis researchers recently looked at data related to 9,000 men with castration-resistant prostate cancer....

  • HIFU Might Not be the Answer for Prostate Cancer Treatment

    High-intensity focused ultrasound has proven itself useful in a number of applications. So far, however, prostate cancer is not one of them. Even so, the U.S. Food and Drug Administration has given the green light for this treatment’s use for the ablation of prostate tissue. This approval has some clinicians concerned. Previous studies have shown that HIFU is not entirely...

  • Red Foods May Lower Prostate Cancer Risk

    The best way to beat prostate cancer is to prevent it in the first place. While this isn’t always possible, there are measures men can take to lower their risks of developing this disease. One of the steps men can take to potentially lower their risks is to incorporate more “red foods” in their diet. Specifically, foods containing lycopene...

  • 6 Prostate Cancer Risk Factors All Men Should Know

    Prostate cancer affects about 180,000 American men each year. Often highly treatable, this disease is frequently beaten by those who manage to detect it early and undergo any treatments deemed necessary for saving lives. An estimated 26,000 American men, however, do die from the disease each year. That makes it especially important for men to understand not only the...

  • Early Puberty Can Increase Prostate Cancer Risk

    Boys who enter puberty at younger ages might be at higher risk for developing prostate cancer down the road. That finding came from a recent study that looked at genetic data related to nearly 3,000 men. Some of the men in the study had prostate cancer and others did not. During the course of the study, researchers found that men...

  • Classifying Intermediate-Risk Prostate Cancer May Help Improve Outcomes

    While many of the 180,000 American men diagnosed with prostate cancer in the upcoming year will find their disease is slow-growing and poses little risk, this isn’t always the case. For men with intermediate risk forms of prostate cancer, radical prostatectomies may be necessary to improve survival chances. This doesn’t mean, however, that all men who undergo this surgery...

  • Prostate Cancer Antiandrogen Therapy: Enzalutamide Offers Strong Results

    For men with asymptomatic or mildly symptomatic metastatic castration -resistant prostate cancer, one antiandrogen drug may work better than a more commonly prescribed option. Research is finding that the drug Enzalutamide performs better than bicalutamide in helping promote progression free survival. Antiandrogen drugs are sometimes used to help treat prostate cancer that is considered aggressive and has spread. This form...